Cosela

Discussion in 'Boehringer Ingelheim' started by anonymous, Feb 27, 2021 at 1:27 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    What’s the level of enthusiasm with oncs for this one? Easy sell or not? Bonus structure?
     

  2. anonymous

    anonymous Guest

    Yawn, GCS-F is a commodity item now.
     
  3. anonymous

    anonymous Guest

    So screw the patients, if they get sick from chemo we’ll just give them filgrastim later because it’s cheap? How about protect them from feeling worse from chemo in the first place.
     
  4. anonymous

    anonymous Guest

    You’re launching a blockbuster and you yawn? Lol. You must be rich.
     
  5. anonymous

    anonymous Guest

    Pssst probably a competitor
     
  6. anonymous

    anonymous Guest

    I think this is a concern for uptake. What are pros cons of just treating negative effects of chemo after the fact with cheap filgrastim? Using Cosela seems like covering the floors before painting the walls vs cleaning paint off the floors afterwards unless it actually is easier/faster/cheaper to clean up after. What are docs saying about value proposition here?